仁普〔苏州)药业有限公司

+ 关注  11发私信

公司信息
  • 公司行业:医疗卫生-有机合成
  • 公司性质:私营企业
  • 公司规模:
  • 公司网址:
  • 联系人:HR
  • 邮政编码:
  • 公司地址:Floor 5th, A5, No.218, Xinghu Street, Suzhou Industrial Park, Suzhou
公司简介

Anti-Cancer Solution Ltd. (ACSL) is a Sino-British pharmaceutical enterprise, headquartered in Suzhou Industrial Park. ACSL is committed to developing affordable drugs for anti-cancer purposes and the treatment of cardiovascular diseases, also the key ingredients as food additive for quality functional food products, and medical devices.

ACSL is currently working on the highly efficient & reproducible processes for the scaled up production of high purity DHA and EPA (chemical purity≥90% and≥96%) as APIs. New products developed based on high purity DHA and EPA will be fed through ACSL’s product pipeline, including: new drugs with our own intellectual proprietary, food additives based on nano-encapsulation technology, and key ingredients as food additive for quality functional products.

Like our company name suggested, anti-cancer drug development will be one of the major goals & objectives in ACSL and is best examplified by our currently ongoing ACS-101 project. As SFDA category one anti-cancer drug, ACS-101 is developed based on attenuation of the Warburg effect during tumoriogenesis. Preliminary clinical results suggested that ACS-101 will be a highly promising new drug in the management of lung cancers, glioblastoma, breast cancer, etc. We are currently working on the scaled up production of API and formulation strategies of ACS-101. The preclinical evaluation of ACS-101(Efficacy, DMPK, Toxicology, etc.) as anti-cancer drug will start in May 2011 and due to complete before May 2012.  It is expected that our IND application to SFDA will be submitted by May 2012. The phase 2 & 3 clinical trials is scheduled to kick-start in 2013, and ACS-101, as a approved new drug by SFDA in the treatment of NSCLC, glioblastoma or breast cancer, etc. will be marketed in 2015-2016 should both the preclinical and clinical works goes according to plan.

R&D team in ACSL is full of quality, with 70% of those holding Master’s degree or PhD. The leading scientist and the current president of ACSL, Dr Yongjun Zhao who once worked as post-doctoral scientist in Imperial College London and as senior scientist in GE healthcare, UK, is full of knowledge and expertise in new drug development. The consultancy team in ACSL is led by Professor Chai Zhi Fang, academician, Chinese Academy of Science, added with a number of well known scientists from Chinese academic institutions and oversea experts in drug development.

ACSL has established and maintained a long term partnership in new drug development with famous institutions like the Institute of High Energy Physics, Chinese Academy of Sciences; the Institute of Biophysics, Chinese Academy of Sciences; the Graduate school of the Chinese Academy of Sciences, Soochow University, Imperial College London, etc.

公司招聘职位

  • 职位名称 招聘人数 薪酬 工作年限 工作地区 更新日期 操作

同行业公司

公司地图